NCT03723512View on ClinicalTrials.gov

Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 6, 2018

Primary Completion Date

February 17, 2021

Study Completion Date

February 17, 2021

Conditions
C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative GlomerulonephritisIC-MPGNDense Deposit Disease
Interventions
DEVICE

Non contrast-enhanced magnetic resonance imaging

Non contrast-enhanced magnetic resonance imaging

Trial Locations (1)

24020

Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, Ranica

Sponsors
All Listed Sponsors
collaborator

Alexion Pharmaceuticals, Inc.

INDUSTRY

lead

Mario Negri Institute for Pharmacological Research

OTHER